glp 1 ra heart failure Glucagon-Like Peptide Receptor Agonist Is Associated With Improved Survival in Overweight Patients The Cardiovascular Biology of Glucagon-like

Given delayed gastric emptying, meal timing and composition require adjustment

No reason to come back tomorrow

If you have diabetes, kidney disease, heart disease, pregnancy, severe stomach symptoms, or dehydration, speak to a qualified doctor before making any treatment decision.[kidney] Key Takeaways GLP-1 medicines began as diabetes and weight-loss drugs, but the bigger story is their GLP-1 heart benefits and GLP-1 kidney benefits

Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss

Weill Professor of Metabolic Research at Weill Cornell